TCRX
Tscan Therapeutics Inc

855
Mkt Cap
$56.25M
Volume
457,861.00
52W High
$2.57
52W Low
$0.8824
PE Ratio
-0.99
TCRX Fundamentals
Price
$0.9885
Prev Close
$1.03
Open
$1.02
50D MA
$1.06
Beta
1.23
Avg. Volume
461,574.98
EPS (Annual)
-$0.9999
P/B
0.46
Rev/Employee
$72,711.27
$71.51
Loading...
Loading...
News
all
press releases
Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care
Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care Combination Therapies Reshape Oncology: A $748B Market Shifts Standard of Care PR Newswire VANCOUVER, BC, March 19, 2026...
PR Newswire·11d ago
News Placeholder
More News
News Placeholder
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Recommendation of "Hold" from Brokerages
Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) have been assigned an average rating of "Hold" from the six brokerages that are currently covering the stock, Marketbeat.com...
MarketBeat·14d ago
News Placeholder
TScan Therapeutics (NASDAQ:TCRX) Downgraded to Sell Rating by Wall Street Zen
Wall Street Zen cut TScan Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...
MarketBeat·16d ago
News Placeholder
HC Wainwright Issues Positive Outlook for TCRX Earnings
TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - HC Wainwright raised their Q1 2026 earnings estimates for TScan Therapeutics in a research note issued on Wednesday, March 4th. HC Wainwright...
MarketBeat·24d ago
News Placeholder
FY2030 Earnings Estimate for TCRX Issued By HC Wainwright
TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Equities research analysts at HC Wainwright issued their FY2030 EPS estimates for shares of TScan Therapeutics in a note issued to investors on...
MarketBeat·25d ago
News Placeholder
TScan Therapeutics (NASDAQ:TCRX) Price Target Raised to $5.00
Wedbush lifted their price target on TScan Therapeutics from $4.00 to $5.00 and gave the stock an "outperform" rating in a research note on Thursday...
MarketBeat·25d ago
News Placeholder
TScan Therapeutics (NASDAQ:TCRX) Releases Quarterly Earnings Results, Beats Estimates By $0.09 EPS
TScan Therapeutics (NASDAQ:TCRX - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate...
MarketBeat·26d ago
News Placeholder
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates
TScan Therapeutics (TCRX) delivered earnings and revenue surprises of +34.31% and -37.08%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·26d ago
News Placeholder
Earnings Breakdown: TScan Therapeutics Q4
read more...
Benzinga·26d ago
News Placeholder
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of +24.11% and +39.36%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
<
1
2
...
>

Latest TCRX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.